CalciMedica (CALC) Net Equity Issued and Repurchased (2019 - 2026)
CalciMedica's (CALC) quarterly Net Equity Issued and Repurchased came in at $8000.0 in Q1 2025, down 99.96% YoY from $19.0 million in Q1 2024, and down 99.91% on a QoQ basis from $8.9 million in Q4 2024.
CalciMedica (CALC) Net Equity Issued and Repurchased (2019 - 2026) Analysis & Trends
CalciMedica (CALC) has 6 years of Net Equity Issued and Repurchased data on file, last reported at $8000.0 in Q1 2025.
- Quarterly Net Equity Issued and Repurchased fell 99.96% year-over-year to $8000.0 in Q1 2025, while the trailing twelve-month figure through Dec 2025 was $8000.0 (down 99.97% YoY) and the FY2025 annual result came in at $8000.0, down 99.97% from the prior year.
- Net Equity Issued and Repurchased eased to $8000.0 in Q1 2025, from $8.9 million in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $19.0 million in Q1 2024 to a low of -$60000.0 in Q2 2024.
- A 4-year average of $7.5 million and a median of $8.9 million in 2024 frame the typical range for Net Equity Issued and Repurchased.
- Annual changes were most pronounced in 2024 — Net Equity Issued and Repurchased jumped 84.17% — and 2025, when it slumped 99.96%.
- Tracing CALC's Net Equity Issued and Repurchased over 4 years: stood at $10.4 million in 2021, then dropped by 0.58% to $10.3 million in 2023, then retreated by 13.71% to $8.9 million in 2024, then slumped by 99.91% to $8000.0 in 2025.
- The last three Net Equity Issued and Repurchased figures came in at $8000.0 (Q1 2025), $8.9 million (Q4 2024), and -$60000.0 (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | CalciMedica | 9.80 Mn | -8.82 Mn | - | 12.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.00 Mn |
| Jun 30, 2026 | 12.00 Mn |
| Mar 31, 2025 | 8,000.00 |
| Mar 31, 2025 | 8,000.00 |
| Dec 31, 2024 | 8.92 Mn |
| Dec 31, 2024 | 8.92 Mn |
| Jun 30, 2024 | -60,000.00 |
| Jun 30, 2024 | -60,000.00 |
| Mar 31, 2024 | 19.04 Mn |
| Mar 31, 2024 | 19.04 Mn |
| Mar 31, 2023 | 10.34 Mn |
| Mar 31, 2023 | 10.34 Mn |
| Jun 30, 2021 | 10.40 Mn |
| Jun 30, 2021 | 10.40 Mn |
| Mar 31, 2021 | 4.10 Mn |
| Mar 31, 2021 | 4.10 Mn |
| Dec 31, 2020 | 12.56 Mn |
| Dec 31, 2020 | 12.56 Mn |
| Dec 31, 2019 | -5,000.00 |
| Dec 31, 2019 | -5,000.00 |